Low-dose 18F-FDG PET/CT enterography: Improving on CT enterography assessment of patients with crohn disease

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1841-1848

  Shyn, Paul B ^a   Mortele, Koenraad J ^a   Britz Cunningham, Scott H ^a   Friedman, Sonia ^a   Odze, Robert D ^a   Burakoff, Robert ^a   Goldberg, Joel E ^a   Erturk, Mehmet ^b   Silverman, Stuart G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

18F FDG; Crohn disease; CT enterography; PET

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; COLESTYRAMINE; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; MERCAPTOPURINE; MESCALINE; NATALIZUMAB; URSODEOXYCHOLIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; COLON FISTULA; COLONOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY ENTEROGRAPHY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENDOSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFLAMMATION; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED DIAGNOSIS; INTESTINE; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; COLONOSCOPY; CONTRAST MEDIA; CROHN DISEASE; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTESTINES; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOMETRY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; YOUNG ADULT;

EID: 78651294997     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.080796     Document Type: Article

References (35)

1. Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85.
2. D'Haens G. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86-92.
3. Cohen R. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103-109.
4. Guimaräes L, Fidler J, Fletcher J, et al. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010;16:226-232.
5. Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut. 2009;58:1113-1120.
6. Lee S, Kim A, Yang S, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology. 2009;251:751-761.
7. Booya F, Fletcher J, Huprich J, et al. Active Crohn disease: CT findings and inter-observer agreement for enteric phase CTenterography. Radiology. 2006;241:787-795.
8. Florie J, Wasser M, Arts-Cieslik K, Akkerman E, Siersema P, Stoker J. Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR. 2006;186:1384-1392.
9. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology. 2009;252:712-720.
10. Bodily K, Fletcher J, Solem C, et al. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography - correlation with endoscopic and histologic findings of inflammation. Radiology. 2006;238:505-516.
11. Sempere G, Sanjuan V, Chulia E, et al. MRI evaluation of inflammatory activity in Crohn's disease. AJR. 2005;184:1829-1835.
12. Choi D, Lee S, Cho Y, et al. Bowel wall thickening in patients with Crohn's disease: CT patterns and correlation with inflammatory activity. Clin Radiol. 2003;58:68-74.
13. 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97:1978-1985.
14. Lemberg D, Issenman R, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:733-738.
15. 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:379-385.
16. Meisner R, Spier B, Einarsson S, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:993-1000.
17. 18F-FDG PET/CT. J Nucl Med. 2007;48:1053-1059.
18. Das C, Makharia G, Kumar R, et al. PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging. 2007;34:2106-2114.
19. Ahmadi A, Li Q, Muller K, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis. 2009;16:974-981.
20. Mettler F, Huda W, Yoshizumi T, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248:254-263.
21. Bongartz G, Golding S, Jurik G, et al. European Guidelines on Quality Criteria for Computed Tomography. Brussels, Belgium: European Commission; 1999.
22. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
23. Harvey R, Bradshaw J. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
24. Guyatt G, Mitchell A, Irvine E, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810. (Pubitemid 19057603)
25. Paulsen S, Huprich J, Fletcher J, et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics. 2006;26:641-662.
26. Hassan C, Cerro P, Zullo A, Spina C, Morini S. Computed tomography enteroclysis in comparison with ileoscopy in patients with Crohn's disease. Int J Colorectal Dis. 2003;18:121-125.
27. 18F-FDG PET/CT. J Nucl Med. 2009;50:1751-1759.
28. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17(suppl 2):11-17.
29. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665. (Pubitemid 39276479)
30. 18F-FDG PET. J Nucl Med. 2009;50(5, suppl):97S-105S.
31. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation. J Am Coll Cardiol. 2006;48:1825-1831.
32. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185-191.
33. Spier B, Perlman S, Jaskowiak C, Reichelderfer M. PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imaging Biol. 2010;12:85-88.
34. Louis E, Collard A, Oger A, et al. Behavior of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782.
35. Yau Y, Chan W, Tam Y, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med. 2005;46:283-291.